#Journal of the American Medical Association

Bristol-Myers Squibb’s daclatasvir, asunaprevir and beclabuvir cured high rates of hepatitis C virus (HCV) among those with genotype 1...

Twelve weeks of Harvoni yielded a 98 percent hepatitis C cure rate among those with genotype 1 of the virus who are coinfected with HIV.

Viekira Pak plus ribavirin boasts a hep C cure rate in the low-90 percent range among those with genotype 1 who are coinfected with HIV.

People who have hepatitis C and advanced liver fibrosis or cirrhosis and are cured of the virus may experience normal lifespan.

Reaching an undetectable hepatitis C viral load is linked to diminished chances of liver disease and liver-related death.

Sofosbuvir and ribavirin demonstrated moderate success in curing a group of people with hepatitis C who had various attributes challenging..

The rates of liver cancer in the United States more than doubled between 1990 and 2010 while deaths resulting from cirrhosis jumped 43 percent...